Accès ouvert
2026
article
OpenAlex
Peyman Hadji, Apostolos Athanasiadis, Maria‐Luisa Brandi, Marlene Chakhtoura et autres
Pregnancy- and lactation-associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. This position statement summarizes the current knowledge of PLO, and the recommended procedure for assessment, diagnosis …
de, gr, it, ca, lb, sg, us, nl, gb, sa, ch, tr, au, ar
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler et autres
Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their …
de, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Manuel Hörner, Lara Tretschock, Nelson John, Philipp Ziegler et autres
PURPOSE: Mutations in PIK3CA are one of several actionable mutations for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Alpelisib in combination with fulvestrant was the first approved PI3K inhibitor and was introduced in clinical practice …
de, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Laura L. Michel, Philipp Kreis, Andreas D. Hartkopf, Markus Wallwiener et autres
INTRODUCTION: Whereas CDK4/6 inhibitors (CDK4/6i) are the standard first-line therapy for patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) metastatic breast cancer, guidelines on treatment options after progression on CDK4/6i are more diverse. Chemotherapy is recommended if a patient develops endocrine resistance or …
de, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Matti Aapro, Peyman Hadji, Daniele Santini, Ralf Schmidmaier et autres
INTRODUCTION: Osteoporosis is a significant public health issue due to its associated morbidity, mortality, and economic burden. Despite available effective treatments, a treatment gap persists, characterized by delayed diagnosis, undertreatment, and poor adherence. Biosimilars, such as biosimilars for denosumab, offer an opportunity …
ch, de, it, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Ulla Stumpf, Ioannis Kyvernitakis, Konstantin Horas, Peyman Hadji
Abstract Poor adherence to oral bisphosphonate therapy remains a major challenge in the treatment of osteoporosis, substantially reducing therapeutic efficacy. While reminder interventions have been proposed as a method to enhance adherence, evidence remains limited. This study aimed to evaluate the impact …
de, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Peyman Hadji, Nasser Al-Dagri, Majed S. Alokail, Emmanuel Biver et autres
Background: Women with hormone-responsive breast cancer who receive adjuvant endocrine treatment with aromatase inhibitors (AI) are known to be at higher fracture risk due to a marked increase in bone resorption. In 2017, several interdisciplinary cancer and bone societies involved in the …
de, ch, sa, be, it, ca, gb, fr, us, au, no, lb, dk, nl, rs, es, at, tr, Afrique du Sud
(code pays fourni par la source)
2025
conference-paper
OpenAlex
Peyman Hadji, S Ferrari, J Trapp, Z Soezen et autres
Zielsetzung: FKS518 ist ein Biosimilar-Kandidat für Denosumab. Ziel dieser Phase-3-Studie (LUMIADE-3, NCT04934072) war die Untersuchung der therapeutischen Äquivalenz zwischen FKS518 und dem Originalpräparat/Referenz-Denosumab bei postmenopausalen Frauen mit Osteoporose, sowie des Einflusses der Umstellung von Referenz-Denosumab auf FKS518. Methoden: LUMINADE-3 ist eine randomisierte, …
de, ch
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
M. Teissonnière, Mathieu Point, Emmanuel Biver, Peyman Hadji et autres
Considerable progress has been made in the management of cancer patients in the last decade with the arrival of anti-cancer immunotherapies (immune checkpoint inhibitors) and targeted therapies. As a result, a broad spectrum of cancers, not just hormone-sensitive ones, have seen several …
fr, ch, de, au, ca, Afrique du Sud, at, be, lb, it, us, in
(code pays fourni par la source)
2025
conference-paper
OpenAlex
AA Kurth, Antonia Müller, K Gazis, P Augath et autres
Einleitung: Chemotherapie-induzierte Osteoporose ist eine iatrogene Nebenwirkung vieler antineoplastischer Behandlungen. Es wird vermutet, dass der durch die Chemotherapie verursachte Östrogenverlust für den Knochenschwund verantwortlich ist, doch deuten zahlreiche Daten auf einen direkten östrogenunabhängigen Mechanismus hin. Direkte negative Auswirkungen einer zytotoxischen Behandlung (z. …
ee, de
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Christina Barbara Walter, Andreas D. Hartkopf, Alexander Hein, Peter A. Fasching et autres
BACKGROUND: Patients with first-line metastatic breast cancer (MBC) comprise patients with de novo metastases (dnMBC) or recurrent disease after primary breast cancer (rMBC). This analysis aimed to explore the prognostic value of dnMBC versus rMBC overall and particularly in subgroups according to …
de, ch
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Peyman Hadji, Luka Kamali, Friederike Thomasius, Konstantin Horas et autres
A retrospective analysis comparing a teriparatide biosimilar (RGB-10) with reference teriparatide for osteoporosis treatment in postmenopausal women at high fracture risk found them to be therapeutically equivalent. Both provided significant improvements in lumber spine BMD, TBS, and other parameters of bone health, …
de
(code pays fourni par la source)